**Author details**

Inelia Morales1,2\*, Gonzalo A. Farías2,3, Nicole Cortes1,2 and Ricardo B. Maccioni1,2,4

\*Address all correspondence to: inelia.morales@gmail.com

1 Laboratory of Cellular and Molecular Neurosciences, Faculty of Sciences, University of Chile, Santiago, Chile

2 International Center for Biomedicine (ICC), Santiago, Chile

3 Department of Neurology and Neurosurgery, Faculty of Medicine, University of Chile, Santiago, Chile

4 Department of Neurological Sciences East, Faculty of Medicine, University of Chile, San‐ tiago, Chile

## **References**

the neuroimmunomodulation hypothesis [48, 58, 145–147] appears as a very plausible explanation for neurodegenerative stereotypical pathogenic process as well as a guide in the

We have also shown that microglial cell has an important role in the neuroinflammation and how this cell is linked with the neurodegenerative processes in these three diseases (**Fig‐ ure 1**). That is, alterations in hippocampal neurons in AD, in motor neurons in ALS, and in dopaminergic neurons of substantia nigra in the PD are linked directly to the inflammatory response of the surrounding altered microglial cells, promoting the neurodegenerative

Another evidence of the effect and the importance of this negative neuroinflammatoryneurodegenerative cycle in the development of these diseases is the experimental response obtained after using compounds with anti-inflammatory properties in AD and ALS [131, 136], turning scientific interest in the development of future treatments that act on abnormal inflammatory response of microglial cell, so that might disrupt the neurodegenerative cycle. Finally, it is of great interest to search for compounds that have fewer adverse effects and at the same time have a preventive action. In this context, the finding of anti-inflammatory and antioxidant properties in natural compounds opens new research possibilities, projecting a possible neuroprotective and anti-neuroinflammatory effects, which based on control of key elements of neuroimmunomodulation hypothesis could be a new tool for the treatment of these

search for new therapeutic and new effective disease-modifying treatments.

This work was supported by CORFO INNOVA CHILE grants 14IEAT-28658.

Inelia Morales1,2\*, Gonzalo A. Farías2,3, Nicole Cortes1,2 and Ricardo B. Maccioni1,2,4

1 Laboratory of Cellular and Molecular Neurosciences, Faculty of Sciences, University of

3 Department of Neurology and Neurosurgery, Faculty of Medicine, University of Chile,

4 Department of Neurological Sciences East, Faculty of Medicine, University of Chile, San‐

\*Address all correspondence to: inelia.morales@gmail.com

2 International Center for Biomedicine (ICC), Santiago, Chile

process.

34 Update on Dementia

diseases.

**Acknowledgements**

**Author details**

Chile, Santiago, Chile

Santiago, Chile

tiago, Chile


[27] Krause DL, Muller N. Neuroinflammation, microglia and implications for antiinflammatory treatment in Alzheimer's disease. Int J Alzheimers Dis. 2010;2010. 10.4061/2010/732806.

[13] Ransohoff RM, Schafer D, Vincent A, Blachere NE, Bar-Or A. Neuroinflammation: ways in which the immune system affects the brain. Neurotherapeutics. 2015 Oct;12(4):

[14] Heneka MT, O'Banion MK. Inflammatory processes in Alzheimer's disease. J Neuro‐

[15] Heneka MT, Golenbock DT, Latz E. Innate immunity in Alzheimer's disease. Nat

[16] Simard AR, Rivest S. Neuroprotective properties of the innate immune system and bone marrow stem cells in Alzheimer's disease. Mol Psychiatry. 2006 Apr;11(4):327-35.

[17] Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 2010

[18] Venneti S, Wiley CA, Kofler J. Imaging microglial activation during neuroinflammation and Alzheimer's disease. J Neuroimmune Pharmacol. 2009 Jun;4(2):227-43. 10.1007/

[19] Perry VH. A revised view of the central nervous system microenvironment and major histocompatibility complex class II antigen presentation. J Neuroimmunol. 1998 Oct

[20] Hanisch UK, Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci. 2007 Nov;10(11):1387-94. 10.1038/nn1997.

[21] Alliot F, Godin I, Pessac B. Microglia derive from progenitors, originating from the yolk sac, and which proliferate in the brain. Brain Res Dev Brain Res. 1999 Nov 18;117(2):

[22] Ginhoux F, Lim S, Hoeffel G, Low D, Huber T. Origin and differentiation of microglia.

[23] Jha MK, Lee WH, Suk K. Functional polarization of neuroglia: implications in neuro‐ inflammation and neurological disorders. Biochem Pharmacol. 2016 Mar 1;103:1-16.

[24] Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, Wilson B, Zhang W, Zhou Y, Hong JS, Zhang J. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J. 2005 Apr;19(6):533-42. 10.1096/

[25] Francis PT. The interplay of neurotransmitters in Alzheimer's disease. CNS Spectr. 2005

[26] Mrak RE. Microglia in Alzheimer brain: a neuropathological perspective. Int J Alz‐

Front Cell Neurosci. 2013;7:45. 10.3389/fncel.2013.00045.

heimers Dis. 2012;2012:165021. 10.1155/2012/165021.

immunol. 2007 Mar;184(1-2):69-91. 10.1016/j.jneuroim.2006.11.017.

Immunol. 2015 Mar;16(3):229-36. 10.1038/ni.3102.

Jan;119(1):7-35. 10.1007/s00401-009-0619-8.

896-909. 10.1007/s13311-015-0385-3.

10.1038/sj.mp.4001809.

36 Update on Dementia

s11481-008-9142-2.

1;90(2):113-21.

145-52.

10.1016/j.bcp.2015.11.003.

Nov;10(11 Suppl 18):6-9.

fj.04-2751com.


[52] Koseoglu E, Karaman Y. Relations between homocysteine, folate and vitamin B12 in vascular dementia and in Alzheimer disease. Clin Biochem. 2007 Aug;40(12):859-63. 10.1016/j.clinbiochem.2007.04.007.

[40] Mrak RE, Sheng JG, Griffin WS. Correlation of astrocytic S100 beta expression with dystrophic neurites in amyloid plaques of Alzheimer's disease. J Neuropathol Exp

[41] Kantarci K, Knopman DS, Dickson DW, Parisi JE, Whitwell JL, Weigand SD, Josephs KA, Boeve BF, Petersen RC, Jack CR, Jr. Alzheimer disease: postmortem neuropatho‐

[42] Tumati S, Martens S, Aleman A. Magnetic resonance spectroscopy in mild cognitive impairment: systematic review and meta-analysis. Neurosci Biobehav Rev. 2013 Dec;

[43] Sillen A, Andrade J, Lilius L, Forsell C, Axelman K, Odeberg J, Winblad B, Graff C. Expanded high-resolution genetic study of 109 Swedish families with Alzheimer's

[44] Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet. 2006 Jul

[45] Weiner HL, Frenkel D. Immunology and immunotherapy of Alzheimer's disease. Nat

[46] McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr., Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheim‐ er's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alz‐

[47] Elbaz A, Dufouil C, Alperovitch A. Interaction between genes and environment in neurodegenerative diseases. C R Biol. 2007 Apr;330(4):318-28. 10.1016/j.crvi.

[48] Maccioni RB, Rojo LE, Fernandez JA, Kuljis RO. The role of neuroimmunomodulation in Alzheimer's disease. Ann N Y Acad Sci. 2009 Feb;1153:240-6. 10.1111/j.

[49] Maccioni RB, Munoz JP, Barbeito L. The molecular bases of Alzheimer's disease and other neurodegenerative disorders. Arch Med Res. 2001 Sep-Oct;32(5):367-81.

[50] Venigalla M, Sonego S, Gyengesi E, Sharman MJ, Munch G. Novel promising thera‐ peutics against chronic neuroinflammation and neurodegeneration in Alzheimer's

[51] Itzhaki RF, Wozniak MA, Appelt DM, Balin BJ. Infiltration of the brain by pathogens causes Alzheimer's disease. Neurobiol Aging. 2004 May-Jun;25(5):619-27. 10.1016/

disease. Neurochem Int. 2016 May;95:63-74. 10.1016/j.neuint.2015.10.011.

disease. Eur J Hum Genet. 2008 Feb;16(2):202-8. 10.1038/sj.ejhg.5201946.

Radiology. 2008 Jul;248(1):210-20. 10.1148/radiol.2481071590.

37(10 Pt 2):2571-86. 10.1016/j.neubiorev.2013.08.004.

29;368(9533):387-403. 10.1016/S0140-6736(06)69113-7.

Rev Immunol. 2006 May;6(5):404-16. 10.1038/nri1843.

heimers Dement. 2011 May;7(3):263-9. 10.1016/j.jalz.2011.03.005.

H MR spectroscopy metabolite measurements.

Neurol. 1996 Mar;55(3):273-9.

38 Update on Dementia

2007.02.018.

1749-6632.2008.03972.x.

j.neurobiolaging.2003.12.021.

logic correlates of antemortem 1


responses and neurotoxicity by PPARgamma agonists. J Neurosci. 2000 Jan 15;20(2): 558-67.


[77] Mackenzie IR, Rademakers R, Neumann M. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol. 2010 Oct;9(10):995-1007. 10.1016/S1474-4422(10)70195-2.

responses and neurotoxicity by PPARgamma agonists. J Neurosci. 2000 Jan 15;20(2):

[65] McGeer PL, McGeer EG. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging. 2007 May;28(5):639-47. 10.1016/j.neuro‐

[66] Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C, Brandt J. Nonsteroidal antiinflammatory drugs in Alzheimer's disease. Neurology. 1995 Jan;45(1):51-5.

[67] Leoutsakos JM, Han D, Mielke MM, Forrester SN, Tschanz JT, Corcoran CD, Green RC, Norton MC, Welsh-Bohmer KA, Lyketsos CG. Effects of general medical health on Alzheimer's progression: the Cache County Dementia Progression Study. Int Psycho‐

[68] Carrasco-Gallardo C, Farias GA, Fuentes P, Crespo F, Maccioni RB. Can nutraceuticals prevent Alzheimer's disease? Potential therapeutic role of a formulation containing shilajit and complex B vitamins. Arch Med Res. 2012 Nov;43(8):699-704. 10.1016/

[69] Cornejo A, Jimenez JM, Caballero L, Melo F, Maccioni RB. Fulvic acid inhibits aggre‐ gation and promotes disassembly of tau fibrils associated with Alzheimer's disease. J

[70] Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med. 2001 May

[71] Wood-Allum C, Shaw PJ. Motor neurone disease: a practical update on diagnosis and

[72] Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci. 2001 Nov;2(11):806-19. 10.1038/35097565.

[73] Pasinelli P, Brown RH. Molecular biology of amyotrophic lateral sclerosis: insights from

[74] Bento-Abreu A, Van Damme P, Van Den Bosch L, Robberecht W. The neurobiology of amyotrophic lateral sclerosis. Eur J Neurosci. 2010 Jun;31(12):2247-65. 10.1111/j.

[75] Ferraiuolo L, Kirby J, Grierson AJ, Sendtner M, Shaw PJ. Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat Rev Neurol. 2011 Nov;7(11):616-30.

[76] Chio A, Calvo A, Mazzini L, Cantello R, Mora G, Moglia C, Corrado L, D'Alfonso S, Majounie E, Renton A, Pisano F, Ossola I, Brunetti M, Traynor BJ, Restagno G, Parals. Extensive genetics of ALS: a population-based study in Italy. Neurology. 2012 Nov

genetics. Nat Rev Neurosci. 2006 Sep;7(9):710-23. 10.1038/nrn1971.

geriatr. 2012 Oct;24(10):1561-70. 10.1017/S104161021200049X.

Alzheimers Dis. 2011;27(1):143-53. 10.3233/JAD-2011-110623.

31;344(22):1688-700. 10.1056/NEJM200105313442207.

management. Clin Med (Lond). 2010 Jun;10(3):252-8.

6;79(19):1983-9. 10.1212/WNL.0b013e3182735d36.

558-67.

40 Update on Dementia

biolaging.2006.03.013.

j.arcmed.2012.10.010.

1460-9568.2010.07260.x.

10.1038/nrneurol.2011.152.


mouse model of amyotrophic lateral sclerosis. Antioxid Redox Signal. 2006 Nov-Dec; 8(11–12):2075-87. 10.1089/ars.2006.8.2075.

[99] Banati RB, Gehrmann J, Kellner M, Holsboer F. Antibodies against microglia/brain macrophages in the cerebrospinal fluid of a patient with acute amyotrophic lateral sclerosis and presenile dementia. Clin Neuropathol. 1995 Jul–Aug;14(4):197-200.

[87] Hooten KG, Beers DR, Zhao W, Appel SH. Protective and toxic neuroinflammation in amyotrophic lateral sclerosis. Neurotherapeutics. 2015 Apr;12(2):364-75. 10.1007/

[88] Liao B, Zhao W, Beers DR, Henkel JS, Appel SH. Transformation from a neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS. Exp Neurol. 2012 Sep;

[89] Zhao W, Beers DR, Appel SH. Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis. J Neuroimmune Pharmacol. 2013 Sep;8(4):888-99.

[90] Chiu IM, Chen A, Zheng Y, Kosaras B, Tsiftsoglou SA, Vartanian TK, Brown RH, Jr., Carroll MC. T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS. Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17913-8. 10.1073/

[91] Gravel M, Beland LC, Soucy G, Abdelhamid E, Rahimian R, Gravel C, Kriz J. IL-10 controls early microglial phenotypes and disease onset in ALS caused by misfolded superoxide dismutase 1. J Neurosci. 2016 Jan 20;36(3):1031-48. 10.1523/JNEUROSCI.

[92] Appel SH, Beers DR, Henkel JS. T cell-microglial dialogue in Parkinson's disease and amyotrophic lateral sclerosis: are we listening? Trends Immunol. 2010 Jan;31(1):7-17.

[93] Beers DR, Zhao W, Liao B, Kano O, Wang J, Huang A, Appel SH, Henkel JS. Neuroin‐ flammation modulates distinct regional and temporal clinical responses in ALS mice.

[94] Lewis CA, Manning J, Rossi F, Krieger C. The neuroinflammatory response in ALS: the roles of microglia and T cells. Neurol Res Int. 2012;2012:803701. 10.1155/2012/803701.

[95] Lewis KE, Rasmussen AL, Bennett W, King A, West AK, Chung RS, Chuah MI. Microglia and motor neurons during disease progression in the SOD1G93A mouse model of amyotrophic lateral sclerosis: changes in arginase1 and inducible nitric oxide

[96] Barbeito AG, Mesci P, Boillee S. Motor neuron-immune interactions: the vicious circle of ALS. J Neural Transm (Vienna). 2010 Aug;117(8):981-1000. 10.1007/

[97] Bowerman M, Vincent T, Scamps F, Perrin FE, Camu W, Raoul C. Neuroimmunity dynamics and the development of therapeutic strategies for amyotrophic lateral

[98] Hensley K, Mhatre M, Mou S, Pye QN, Stewart C, West M, Williamson KS. On the relation of oxidative stress to neuroinflammation: lessons learned from the G93A-SOD1

sclerosis. Front Cell Neurosci. 2013 Nov 19;7:214. 10.3389/fncel.2013.00214.

Brain Behav Immun. 2011 Jul;25(5):1025-35. 10.1016/j.bbi.2010.12.008.

synthase. J Neuroinflammation. 2014;11:55. 10.1186/1742-2094-11-55.

s13311-014-0329-3.

42 Update on Dementia

10.1007/s11481-013-9489-x.

pnas.0804610105.

0854-15.2016.

10.1016/j.it.2009.09.003.

s00702-010-0429-0.

237(1):147-52. 10.1016/j.expneurol.2012.06.011.


ity and free [Ca2+]i responses. Mol Biol Cell. 2008 Aug;19(8):3501-13. 10.1091/ mbc.E07-12-1240.


[121] Lu C, Guo Y, Yan J, Luo Z, Luo HB, Yan M, Huang L, Li X. Design, synthesis, and evaluation of multitarget-directed resveratrol derivatives for the treatment of Alz‐ heimer's disease. J Med Chem. 2013 Jul 25;56(14):5843-59. 10.1021/jm400567s.

ity and free [Ca2+]i responses. Mol Biol Cell. 2008 Aug;19(8):3501-13. 10.1091/

[111] Bosch M, Kielian T. Hemichannels in neurodegenerative diseases: is there a link to

[112] Takeuchi H, Mizoguchi H, Doi Y, Jin S, Noda M, Liang J, Li H, Zhou Y, Mori R, Yasuoka S, Li E, Parajuli B, Kawanokuchi J, Sonobe Y, Sato J, Yamanaka K, Sobue G, Mizuno T, Suzumura A. Blockade of gap junction hemichannel suppresses disease progression in mouse models of amyotrophic lateral sclerosis and Alzheimer's disease. PLoS One.

[113] Bruck D, Wenning GK, Stefanova N, Fellner L. Glia and alpha-synuclein in neurode‐ generation: a complex interaction. Neurobiol Dis. 2016 Jan;85:262-74. 10.1016/j.nbd.

[114] Collins LM, Toulouse A, Connor TJ, Nolan YM. Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease. Neuropharmacology.

[115] Martin HL, Santoro M, Mustafa S, Riedel G, Forrester JV, Teismann P. Evidence for a role of adaptive immune response in the disease pathogenesis of the MPTP mouse

model of Parkinson's disease. Glia. 2016 Mar;64(3):386-95. 10.1002/glia.22935.

[116] Sun H, Liang R, Yang B, Zhou Y, Liu M, Fang F, Ding J, Fan Y, Hu G. Aquaporin-4 mediates communication between astrocyte and microglia: implications of neuroin‐ flammation in experimental Parkinson's disease. Neuroscience. 2016 Mar 11;317:65-75.

[117] Meiser J, Delcambre S, Wegner A, Jager C, Ghelfi J, d'Herouel AF, Dong X, Weindl D, Stautner C, Nonnenmacher Y, Michelucci A, Popp O, Giesert F, Schildknecht S, Kramer L, Schneider JG, Woitalla D, Wurst W, Skupin A, Weisenhorn DM, Kruger R, Leist M, Hiller K. Loss of DJ-1 impairs antioxidant response by altered glutamine and serine

metabolism. Neurobiol Dis. 2016 May;89:112-25. 10.1016/j.nbd.2016.01.019.

[118] Barber SC, Higginbottom A, Mead RJ, Barber S, Shaw PJ. An in vitro screening cascade to identify neuroprotective antioxidants in ALS. Free Radic Biol Med. 2009 Apr 15;46(8):

[119] Lin Y, Chen F, Zhang J, Wang T, Wei X, Wu J, Feng Y, Dai Z, Wu Q. Neuroprotective effect of resveratrol on ischemia/reperfusion injury in rats through TRPC6/CREB

[120] Singh N, Agrawal M, Dore S. Neuroprotective properties and mechanisms of resvera‐ trol in in vitro and in vivo experimental cerebral stroke models. ACS Chem Neurosci.

pathways. J Mol Neurosci. 2013 Jul;50(3):504-13. 10.1007/s12031-013-9977-8.

pathology? Front Cell Neurosci. 2014;8:242. 10.3389/fncel.2014.00242.

2011;6(6):e21108. 10.1371/journal.pone.0021108.

10.1016/j.neuroscience.2016.01.003.

1127-38. 10.1016/j.freeradbiomed.2009.01.019.

2013 Aug 21;4(8):1151-62. 10.1021/cn400094w.

2012 Jun;62(7):2154-68. 10.1016/j.neuropharm.2012.01.028.

mbc.E07-12-1240.

44 Update on Dementia

2015.03.003.


[143] Pereira A. Glutamatergic Dysfunction in Cognitive Aging: Riluzole in Mild Alzheimer's Disease. Phase 2, Clinical Study, 2016. Available from: https://clinicaltrials.gov/ct/ show/NCT01703117.

[132] Ambegaokar SS, Wu L, Alamshahi K, Lau J, Jazayeri L, Chan S, Khanna P, Hsieh E, Timiras PS. Curcumin inhibits dose-dependently and time-dependently neuroglial cell

[133] Giri RK, Rajagopal V, Kalra VK. Curcumin, the active constituent of turmeric, inhibits amyloid peptide-induced cytochemokine gene expression and CCR5-mediated chemotaxis of THP-1 monocytes by modulating early growth response-1 transcription factor. J Neurochem. 2004 Dec;91(5):1199-210. 10.1111/j.1471-4159.2004.02800.x. [134] Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, Cole GM. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem. 2005

[135] Cox KH, Pipingas A, Scholey AB. Investigation of the effects of solid lipid curcumin on cognition and mood in a healthy older population. J Psychopharmacol. 2015 May;29(5):

[136] Dong H, Xu L, Wu L, Wang X, Duan W, Li H, Li C. Curcumin abolishes mutant TDP-43 induced excitability in a motoneuron-like cellular model of ALS. Neuroscience. 2014

[137] Fumagalli E, Funicello M, Rauen T, Gobbi M, Mennini T. Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1. Eur J Pharmacol. 2008 Jan

[138] Grant P, Song JY, Swedo SE. Review of the use of the glutamate antagonist riluzole in psychiatric disorders and a description of recent use in childhood obsessive-compul‐ sive disorder. J Child Adolesc Psychopharmacol. 2010 Aug;20(4):309-15. 10.1089/cap.

[139] Kennel P, Revah F, Bohme GA, Bejuit R, Gallix P, Stutzmann JM, Imperato A, Pratt J. Riluzole prolongs survival and delays muscle strength deterioration in mice with progressive motor neuronopathy (pmn). J Neurol Sci. 2000 Nov 1;180(1-2):55-61. [140] Gurney ME, Fleck TJ, Himes CS, Hall ED. Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis. Neurology. 1998 Jan;50(1):

[141] Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2007 (1):CD001447.

[142] Scimemi A, Meabon JS, Woltjer RL, Sullivan JM, Diamond JS, Cook DG. Amyloidbeta1-42 slows clearance of synaptically released glutamate by mislocalizing astrocytic GLT-1. J Neurosci. 2013 Mar 20;33(12):5312-8. 10.1523/JNEUROSCI.5274-12.2013.

proliferation and growth. Neuro Endocrinol Lett. 2003 Dec;24(6):469-73.

Feb 18;280(7):5892-901. 10.1074/jbc.M404751200.

Jul 11;272:141-53. 10.1016/j.neuroscience.2014.04.032.

14;578(2-3):171-6. 10.1016/j.ejphar.2007.10.023.

642-51. 10.1177/0269881114552744.

10.1002/14651858.CD001447.pub2.

2010.0009.

46 Update on Dementia

62-6.

